SI-BONE, Inc. (NASDAQ:SIBN) Shares Sold by Credit Suisse AG

Credit Suisse AG decreased its holdings in shares of SI-BONE, Inc. (NASDAQ:SIBN) by 41.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 21,310 shares of the company’s stock after selling 15,020 shares during the period. Credit Suisse AG owned approximately 0.06% of SI-BONE worth $677,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Dorsey Wright & Associates increased its position in SI-BONE by 135.0% during the 1st quarter. Dorsey Wright & Associates now owns 1,128 shares of the company’s stock worth $36,000 after purchasing an additional 648 shares during the period. Susquehanna International Group LLP increased its position in SI-BONE by 7.9% during the 4th quarter. Susquehanna International Group LLP now owns 12,262 shares of the company’s stock worth $367,000 after purchasing an additional 896 shares during the period. Altshuler Shaham Ltd acquired a new position in SI-BONE during the 1st quarter worth approximately $42,000. Lazard Asset Management LLC acquired a new position in SI-BONE during the 4th quarter worth approximately $41,000. Finally, American International Group Inc. increased its position in SI-BONE by 10.7% during the 4th quarter. American International Group Inc. now owns 16,791 shares of the company’s stock worth $502,000 after purchasing an additional 1,618 shares during the period. Institutional investors own 89.10% of the company’s stock.

In other SI-BONE news, Director Jeryl L. Hilleman sold 4,400 shares of the stock in a transaction on Friday, June 25th. The stock was sold at an average price of $33.71, for a total transaction of $148,324.00. Following the transaction, the director now owns 198,091 shares of the company’s stock, valued at approximately $6,677,647.61. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jeffrey W. Dunn sold 2,113 shares of the stock in a transaction on Friday, July 16th. The stock was sold at an average price of $29.10, for a total value of $61,488.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 150,479 shares of company stock worth $4,818,807. 15.50% of the stock is owned by corporate insiders.

Several equities analysts have issued reports on SIBN shares. Needham & Company LLC boosted their target price on SI-BONE from $34.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, May 4th. Truist Securities upped their price target on SI-BONE from $35.00 to $43.00 in a report on Tuesday, May 4th. Citigroup began coverage on SI-BONE in a report on Tuesday, June 8th. They issued a “buy” rating on the stock. Morgan Stanley upped their price target on SI-BONE from $38.00 to $41.00 and gave the stock an “overweight” rating in a report on Tuesday, May 4th. Finally, began coverage on SI-BONE in a report on Tuesday, June 8th. They issued a “buy” rating and a $40.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. SI-BONE has an average rating of “Buy” and a consensus target price of $38.50.

SIBN stock opened at $30.71 on Thursday. SI-BONE, Inc. has a 1 year low of $16.25 and a 1 year high of $37.21. The company has a current ratio of 15.18, a quick ratio of 14.64 and a debt-to-equity ratio of 0.24. The company has a 50 day moving average of $30.90. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of -21.63 and a beta of 1.44.

SI-BONE (NASDAQ:SIBN) last posted its earnings results on Sunday, May 2nd. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.03. SI-BONE had a negative return on equity of 31.92% and a negative net margin of 56.06%. The firm had revenue of $20.44 million for the quarter, compared to analyst estimates of $19.08 million. On average, analysts anticipate that SI-BONE, Inc. will post -1.58 EPS for the current year.

About SI-BONE

SI-BONE, Inc, a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain.

Featured Story: What are gap-down stocks?

Want to see what other hedge funds are holding SIBN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SI-BONE, Inc. (NASDAQ:SIBN).

Institutional Ownership by Quarter for SI-BONE (NASDAQ:SIBN)

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.